Legendary artist Bob Dylan is set to perform at Ball State University in Muncie in 2026. The Rough and Rowdy Ways World Wide ...

Dec 23 () - The market for weight-loss drug is expected to expand to more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo ...

Novo Nordisk's newly approved weight-loss pill version of Wegovy will be a test case for the fast-growing cash-paying ...

For the last installment of the America in Focus project this year, we spoke with 14 Americans from all walks of life who are ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Starting in 2026, people who are insured through Medicare will pay no more than $2,100 out of pocket on prescription drugs over the year. That cap may be much lower than $2,100 due to a quirk in ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...

Dec 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S.